Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Birth control pill vs. vaginal ring: which is better for your bones?

NCT ID NCT02367846

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study compares the effects of oral contraceptive pills and a contraceptive vaginal ring on bone turnover in young, exercising women aged 18-25. Using a special calcium tracer, researchers measure how each method changes bone calcium balance over 49 days. The goal is to understand whether the route of hormone delivery influences bone health, which could guide contraceptive choices for active women.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ethinyl estradiol (combined oral contraceptive and contraceptive vaginal ring)
What this could lead to
If it works, this could help women choose a contraceptive method that minimizes bone loss, especially for those at risk of osteoporosis.
What could go wrong
This is a very small early-phase study with only 6 participants, so results may not apply to all women. The intervention is short-term, and long-term bone effects remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

6 people

The number who actually took part.

Started

Jan 2015

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 25 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female 2. Age 18-25 yrs 3. BMI 18-29 kg/m2 4. Non-smoking 5. Willing to refrain from using hormonal contraceptives for the equilibration + baseline period of the study (\~150 days) 6. Availability to frequently visit the laboratory in the next 12 months 7. Not currently pregnant nor intending to become pregnant in the next 12 months 8. Not lactating 9. No apparent metabolic, endocrine, musculoskeletal, or severe psychiatric disease 10. Willing to maintain consistent exercise (aerobic, weight-bearing) and dietary habits during pre-intervention and intervention periods 11. Willing to refrain from supplements other than those provided by study staff in the next 12 months 12. Variable physical activity acceptable, but mode must be primarily weight bearing 13. At least 9 menses in the past 12 months Exclusion Criteria: 1. Non-weight bearing exercise as primary mode of physical activity 2. Resistance exercise training (≥ 2 times 30 minutes per week of resistance exercise) 3. Complete seasonal change of impact mode of physical activity 4. Known or suspected metabolic or endocrine disease 5. Smoking 6. Pregnant 7. Currently consuming large amounts of soy products 8. Current clinical eating disorder or other axis 1 psychiatric disorder or bipolar disorders 9. Oral or hormonal contraceptive use in the last 6 months 10. Hyperparathyroidism 11. Liver or renal disease 12. Evidence of malabsorption or skeletal disorder 13. Thyroid abnormalities (controlled hypothyroidism acceptable) 14. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDS) 15. Taking medications known to have interactions with oral or vaginal contraceptive therapy 16. Other Exclusion Criteria proposed by the World Health Organization COC Contraindications (Grossman et al., 2011).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Other disorders of bone development and growth are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Women's Health and Exercise Laboratories, The Pennsylvania State University

    University Park, Pennsylvania, 16802, United States